Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01055015 · ClinicalTrials.gov registry record · Phase 3
Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty
A Phase 3 study, sponsored by QRxPharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
NCT01055015 is a Phase 3 study that has completed, run by QRxPharma. The registered enrollment target is 141 participants.
The verdict
NCT01055015, a Phase 3 study, has completed, sponsored by QRxPharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
Study Summary
This is a Phase 3, two-arm, double-blind study of efficacy and safety of Q8003 in patients who have undergone primary unilateral total knee arthroplasty
Interventions
- DRUG Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)
- DRUG Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01055015
The ClinicalTrials.gov registry entry for NCT01055015 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is QRxPharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride) is the first listed.
NCT01055015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01055015 about?
NCT01055015 is a clinical study titled "Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty". This is a Phase 3, two-arm, double-blind study of efficacy and safety of Q8003 in patients who have undergone primary unilateral total knee arthroplasty
What is the current status of trial NCT01055015?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2010-02. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01055015?
The interventions under investigation include: Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride) (DRUG), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride) (DRUG).
Who is sponsoring clinical trial NCT01055015?
This trial is sponsored by QRxPharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.